The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma

Relapsed and refractory (R/R) multiple myeloma (MM) constitutes a specific and unmet medical need. Median survival ranges from as little as 6 to 9 months, and responses to treatment are characteristically short. In patients with R/R MM after therapy of bortezomib and/or immunomodulators a bendamusti...

Full description

Saved in:
Bibliographic Details
Main Authors: S. V. Voloshin, S. S. Bessmeltsev, T. P. Zagoskina, N. V. Medvedeva, K. D. Kaplanov, E. V. Karyagina, A. D. Garifullin, A. Yu. Kuvshinov, L. V. Stelmashenko, K. M. Abdulkadyrov
Format: Article
Language:Russian
Published: ABV-press 2015-10-01
Series:Онкогематология
Subjects:
multiple myeloma
bendamustine
bortezomib
lenalidomide
stem cells transplantation
genetic abnormalities
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/149
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://oncohematology.abvpress.ru/ongm/article/view/149

Similar Items